Drug Profile
Oncolysin CD6
Alternative Names: Anti-CD6-blocked ricin; Anti-T12-blocked ricinLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; ImmunoGen; Nonindustrial source
- Developer ImmunoGen; Nonindustrial source
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Leukaemia; Lymphoma; Renal transplant rejection; Systemic lupus erythematosus
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 25 Nov 1998 Discontinued-I for Leukaemia in USA (IV-infusion)
- 25 Nov 1998 Discontinued-I for Lymphoma in USA (IV-infusion)